This HTML5 document contains 273 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n12http://dx.doi.org/10.2147/

Statements

Subject Item
wd:Q35128716
rdf:type
wikibase:Item
schema:description
2011년 논문 vitenskapelig artikkel научна статия artykuł naukowy artikulong pang-agham 2011 թվականի հունիսին հրատարակված գիտական հոդված tudományos cikk مقالهٔ علمی vědecký článek vedecký článok 2011年论文 سائنسی مضمون 2011年論文 2011年論文 articol științific vetenskaplig artikel artigo científico (publicado na 2011) מאמר מדעי 2011年论文 naučni članak 2011年論文 2011 nî lūn-bûn научни чланак artigo científico scienca artikolo article científic article scientifique (publié 2011) 2011年论文 mokslinis straipsnis videnskabelig artikel (udgivet 2011) научная статья 2011 թուականի Յունիսին հրատարակուած գիտական յօդուած مقالة علمية artículu científicu espublizáu en 2011 2011年论文 บทความทางวิทยาศาสตร์ bài báo khoa học artikull shkencor article scientific scientific article научни чланак 2011年論文 2011年论文 мақолаи илмӣ наукова стаття, опублікована в червні 2011 2011年論文 bilimsel makale мақолаи илмӣ tieteellinen artikkeli artículo científico publicado en 2011 artigo científico (publicado na 2011) 2011年论文 wissenschaftlicher Artikel vitskapeleg artikkel επιστημονικό άρθρο სამეცნიერო სტატია 2011年の論文 articolo scientifico ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ teaduslik artikkel wetenschappelijk artikel
p:P577
wds:Q35128716-C266AE9A-1070-4C3E-BE75-EC69A0EE5AA9
wdt:P577
2011-06-29T00:00:00Z
p:P407
wds:Q35128716-5664EC9D-5F58-4F3D-95F7-A7D4070CEBF6
wdt:P407
wd:Q1860
p:P2860
wds:Q35128716-A5D039CC-7813-4706-8367-2CD9416A84E0 wds:Q35128716-A6951C58-C1DE-4C35-BAFA-D061C41457BF wds:Q35128716-9105BBB0-EC99-4D41-8416-B8C496442EF2 wds:Q35128716-95D62206-4202-434E-ABDA-CE38FBFE3E00 wds:Q35128716-95EF5D78-E756-4B19-9D92-9E0F842F47D5 wds:Q35128716-9D2A3482-A204-4D1B-8AFC-FD8543F82E43 wds:Q35128716-8C68DAD4-9B5B-4DEB-A190-9D98189DE2B6 wds:Q35128716-8C8F7CBC-1525-441E-B55E-813EE4B825FF wds:Q35128716-8D277EB9-1DEB-4AB6-9F78-21155CBECB18 wds:Q35128716-8D6C0404-12DB-49BA-AC23-513CEABAF42B wds:Q35128716-7E97035E-8B02-4003-9064-B0AF20EA3798 wds:Q35128716-863C8E05-7E53-4148-9BA5-72B2B5FA87BB wds:Q35128716-8AE57ACD-8B4E-46CE-BA64-B5226AA9603A wds:Q35128716-7425DF5B-5CB6-4254-8C1C-4E77D16D064B wds:Q35128716-7561C761-AD66-4017-9A4B-0D9DF54F62E9 wds:Q35128716-78E2DF56-8032-4C98-80C8-FAD6CC87C48A wds:Q35128716-796B9507-22E5-4422-9641-30BB156392B0 wds:Q35128716-6D0ADE08-D61C-48AA-9528-2E9A4F98D63A wds:Q35128716-6DB478B5-25FA-40FB-81C2-4A62D700BE26 wds:Q35128716-6F5C2CB1-00FA-489B-BFC1-FF9918F1E5EC wds:Q35128716-715D1B23-61A0-4EDD-8894-D86693DCDFD3 wds:Q35128716-59805CD6-8B22-4EE8-A42A-39762064C03C wds:Q35128716-5EB031BC-36BF-45DF-8D4F-5B477131A984 wds:Q35128716-63DF9253-5711-49F9-866F-06A828048AD9 wds:Q35128716-64817712-6D5A-4279-AF6E-6F563B25939E wds:Q35128716-52F2A427-7A5F-448A-AF84-F50848CBE6D9 wds:Q35128716-55C3BD22-7B34-4AF6-9D63-2C597B7F09AC wds:Q35128716-45E89711-E2D1-4F98-AEBC-59CBBABECE53 wds:Q35128716-47FE0EA7-B6C4-441B-993A-1027B8F96FA0 wds:Q35128716-502B30F1-2A70-46F2-8E71-9394B1B0FF9C wds:Q35128716-30BECD98-16BD-4566-8E1C-A1DD2E4E9954 wds:Q35128716-397D4DEA-688D-4A0A-8768-F37F3FB04DD8 wds:Q35128716-3AB7C903-DA8F-4C61-9D88-D0CD1213F81B wds:Q35128716-3F3970C5-4E53-4401-81B1-CBB2504E5BA3 wds:Q35128716-22B233DC-3867-4BC6-9C27-39E18DCE4655 wds:Q35128716-29BB00FD-3F39-48C2-A433-60D96D39B079 wds:Q35128716-2E766711-F0D5-484B-B0DB-904994806136 wds:Q35128716-304AD9EE-7AAE-476F-AEC6-C073E8808183 wds:Q35128716-1AA60D4B-BEB0-4A55-95B6-D3AD4EFF60E3 wds:Q35128716-1B33652E-7646-4EBA-9D9C-1CDA77887981 wds:Q35128716-1C9A5DB2-E7AF-40FC-96F8-2F13FF62C1D3 wds:Q35128716-150BD552-C955-4774-A9E8-CDDC88BBAA31 wds:Q35128716-166BAD86-7781-4CAE-BEB3-1EAC4D386012 wds:Q35128716-1944553C-D4F7-47CB-9152-ADCD3006A1EE wds:Q35128716-13F2A457-19EC-4B04-A7E6-C2A432F3CBCC wds:Q35128716-0A693651-F469-4B47-A332-EFC45DE3856E wds:Q35128716-0B53CB8A-47C2-4DCC-8784-C68BC062F100 wds:Q35128716-0C752DBE-C242-4E82-A433-C1CBACCA1517 wds:Q35128716-0DA29C89-E836-4D9B-8C67-21BB407DAFF8 wds:Q35128716-04DD90EC-F19C-4CF9-BC97-23750B9022C6 wds:Q35128716-053FA8EC-E359-4300-A995-D14B66565D8E wds:Q35128716-0668BDF2-481A-4E28-B6B0-F8102E8FADBF wds:Q35128716-06D01DE6-7725-44E7-BD7F-0E803F57F4F1 wds:Q35128716-F02F7704-84E4-4527-81DA-B87A519EA0CA wds:Q35128716-F0F88F07-8EE8-49E0-8560-D28D2A7D6C70 wds:Q35128716-E642821F-7EBE-49E3-9F75-CB57D7FFF1CB wds:Q35128716-EC469A64-33D6-40D2-9608-47DC96F5B112 wds:Q35128716-EDF6C05A-EAA9-4591-A8B3-B06E90438401 wds:Q35128716-EE129B42-54AA-4784-A761-C8360D577A1F wds:Q35128716-E02874D6-181E-415A-914E-C17818D8F43D wds:Q35128716-E2D1DB12-C422-43B5-B997-5ACD4C0481E2 wds:Q35128716-E3D4F5EC-F805-422B-9279-11907D405154 wds:Q35128716-E635D80B-BBA1-4501-B9C0-6A4F2CA5E229 wds:Q35128716-DA1DC645-3F45-4122-8B05-95386EFECAA9 wds:Q35128716-DCA9C3F4-C7BD-4658-AB9B-0711BE4FB307 wds:Q35128716-DEF86C70-9010-4B83-BCA4-7F0A6FDB22B2 wds:Q35128716-DF3D8FA9-18E5-4B4E-B280-FF18D5E1E52E wds:Q35128716-CC48A575-7F60-4488-ACDC-A7C975F2D41E wds:Q35128716-CCECD704-1CFB-4F99-9C3B-4786BF4FF76C wds:Q35128716-B9516FCE-C199-4BCF-9EDE-FBDA590F3A68 wds:Q35128716-C726F8A0-8071-4990-8635-64046268BCC0 wds:Q35128716-C93CAC2F-DF32-40EF-B26A-5A0163421BE2 wds:Q35128716-B0C02079-A174-4AEA-9B5D-FE4A8F2B5DAC wds:Q35128716-B6269986-551E-46E1-A1AF-C9AF6C832437 wds:Q35128716-B7635540-7BA5-4B5A-8E97-12E5C11388AE wds:Q35128716-B78A9EF6-1626-48A6-A140-E3AB98F94D7A wds:Q35128716-ADEA7425-47C8-416D-B56C-6D4435A8A067 wds:Q35128716-AFFCBC81-684E-4355-8F1C-BABBD76FF099 wds:Q35128716-B07B1084-C4AA-4398-9093-3C4BB50D93A5 wds:Q35128716-A9471C58-73F9-4A74-B5EC-021529EAEED1 wds:Q35128716-ABD93059-C259-45E3-8BA6-783AB4B9248B wds:Q35128716-ADB79307-969D-49F1-BFAD-8DAD9EEE8003 wds:Q35128716-ADD687D8-5F2E-4BCF-8F8A-0753C1DD4F74 wds:Q35128716-02650A96-10F5-4271-B2C7-DD833C968BBE
wdt:P2860
wd:Q46252104 wd:Q36504117 wd:Q41700274 wd:Q40915955 wd:Q36707712 wd:Q81160948 wd:Q74650210 wd:Q37738797 wd:Q53622998 wd:Q43514503 wd:Q43921221 wd:Q33318333 wd:Q44799712 wd:Q37455348 wd:Q46578425 wd:Q33223730 wd:Q74310288 wd:Q33734281 wd:Q34447732 wd:Q39763380 wd:Q36183805 wd:Q34513511 wd:Q27860918 wd:Q36058291 wd:Q53964246 wd:Q36778558 wd:Q37829042 wd:Q34080914 wd:Q68976093 wd:Q33470429 wd:Q39958481 wd:Q37149028 wd:Q36896020 wd:Q37347503 wd:Q73924100 wd:Q36981678 wd:Q24646000 wd:Q28139062 wd:Q33386511 wd:Q43590583 wd:Q46817220 wd:Q35219026 wd:Q36473831 wd:Q24633115 wd:Q37633545 wd:Q24596926 wd:Q57385846 wd:Q44222779 wd:Q37317709 wd:Q36433781 wd:Q37387347 wd:Q53258564 wd:Q72076251 wd:Q40813169 wd:Q33566395 wd:Q40619448 wd:Q27860525 wd:Q37331219 wd:Q34600965 wd:Q33767866 wd:Q27860648 wd:Q37169042 wd:Q52011697 wd:Q73489469 wd:Q42277004 wd:Q44398113 wd:Q40272654 wd:Q37829694 wd:Q40494172 wd:Q29616123 wd:Q29616218 wd:Q33926746 wd:Q34543188 wd:Q37161838 wd:Q34151732 wd:Q34578443 wd:Q71692636 wd:Q73699220 wd:Q33770374 wd:Q70898056 wd:Q79794482 wd:Q40881281 wd:Q29620155 wd:Q36516414
p:P2093
wds:Q35128716-4AE95ED6-8335-49D3-9C8D-850EC52DD0DB wds:Q35128716-A0F38D8D-DA2F-4979-9450-767782D65EAA wds:Q35128716-81F14F28-AD13-49D5-B789-408AD4508C74
wdt:P2093
Mayer Fishman Shilpa Gupta Estrella Carballido
rdfs:label
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
skos:prefLabel
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
schema:name
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
p:P1476
wds:Q35128716-1815E20C-CBB7-4DD5-A0CF-47F41F2299B6
wdt:P1476
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
p:P304
wds:Q35128716-CFBF3A4E-3862-4CFA-B3E0-A19B7C50FA2D
wdt:P304
79-96
p:P31
wds:Q35128716-11db6800-607b-431a-8785-5ea3455464b2 wds:Q35128716-1E31E396-9A01-4F26-88D2-2FA2B5483459
wdt:P31
wd:Q13442814 wd:Q7318358
p:P698
wds:Q35128716-AEA5A22F-BB45-43AF-B8CA-D39B03225299
wdtn:P698
n10:21792315
wdt:P698
21792315
p:P1433
wds:Q35128716-11284109-8381-4491-88C4-DAE17145E41A
wdt:P1433
wd:Q7092081
p:P478
wds:Q35128716-CF3AF6DB-21FC-4FEF-A70D-413010C11AF3
wdt:P478
4
p:P356
wds:Q35128716-58C1CF87-4906-4CC8-9A5D-A4850C5D7CEE
wdtn:P356
n12:OTT.S14107
wdt:P356
10.2147/OTT.S14107
p:P275
wds:Q35128716-ed64df91-d7b6-4309-813d-16f15a9953de
p:P6216
wds:Q35128716-0aee00e0-8c08-48d7-b261-812b4dec8f8f
wdt:P275
wd:Q18810331
wdt:P6216
wd:Q50423863
p:P932
wds:Q35128716-A2760038-5F70-44C4-AC8E-B7C7950455D8
wdt:P932
3143908